Cipla Recall
- All
- News
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Dr Reddy's, Cipla, Aurobindo Units Recall Products From US Market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.
-
Cipla Recalls over 1.4 lakh Vials of Asthma Drug in US
As per the information available on the USFDA website, Cipla is recalling the drug for "failed impurities and degradation specifications".
-
Nomura upgrades Ranbaxy to 'buy' on expectations of better margins
Global brokerage Nomura has upgraded the stock of drug major Ranbaxy to a buy from neutral, and set its 12-month target price at Rs 475.
-
Ranbaxy surprises with Q4 loss, sees modest sales growth in 2013
Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said its base business would grow a modest 10 per cent in 2013 after reporting a surprise quarterly loss on product recall charges, sending its shares down more than 4 per cent.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Dr Reddy's, Cipla, Aurobindo Units Recall Products From US Market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.
-
Cipla Recalls over 1.4 lakh Vials of Asthma Drug in US
As per the information available on the USFDA website, Cipla is recalling the drug for "failed impurities and degradation specifications".
-
Nomura upgrades Ranbaxy to 'buy' on expectations of better margins
Global brokerage Nomura has upgraded the stock of drug major Ranbaxy to a buy from neutral, and set its 12-month target price at Rs 475.
-
Ranbaxy surprises with Q4 loss, sees modest sales growth in 2013
Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said its base business would grow a modest 10 per cent in 2013 after reporting a surprise quarterly loss on product recall charges, sending its shares down more than 4 per cent.
